ID | 54982 |
JaLCDOI | |
フルテキストURL | |
著者 |
Mori, Akihiro
Department of Urology, Okayama University, Graduate School of Medicine, Denistry and Pharmacentical Sciences
Watanabe, Masami
Department of Urology, Okayama University, Graduate School of Medicine, Denistry and Pharmacentical Sciences
Kaken ID
publons
researchmap
Sadahira, Takuya
Department of Urology, Okayama University, Graduate School of Medicine, Denistry and Pharmacentical Sciences
Kobayashi, Yasuyuki
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
Ariyoshi, Yuichi
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Ueki, Hideo
Department of Urology, Okayama University, Graduate School of Medicine, Denistry and Pharmacentical Sciences
Wada, Koichiro
Department of Urology, Okayama University, Graduate School of Medicine, Denistry and Pharmacentical Sciences
ORCID
researchmap
Ochiai, Kazuhiko
Department of Veterinary Nursing and Technology, Nippon Veterinary and Life Science University
Li, Shun-Ai
Center for Innovative Clinical Medicine, Okayama University Hospital
Nasu, Yasutomo
Department of Urology, Okayama University, Graduate School of Medicine, Denistry and Pharmacentical Sciences
Kaken ID
publons
researchmap
|
抄録 | The cluster of differentiation 147 (CD147), also known as EMMPRIN, is a key molecule that promotes cancer progression. We previously developed an adenoviral vector encoding a tumor suppressor REIC/Dkk-3 gene (Ad-REIC) for cancer gene therapy. The therapeutic effects are based on suppressing the growth of cancer cells, but, the underlying molecular mechanism has not been fully clarified. To elucidate this mechanism, we investigated the effects of Ad-REIC on the expression of CD147 in LNCaP prostate cancer cells. Western blotting revealed that the expression of CD147 was significantly suppressed by Ad-REIC. Ad-REIC also suppressed the cell growth of LNCaP cells. Since other researchers have demonstrated that phosphorylated mitogen-activated protein kinases (MAPKs) and c-Myc protein positively regulate the expression of CD147, we investigated the correlation between the CD147 level and the activation of MAPK and c-Myc expression. Unexpectedly, no positive correlation was observed between CD147 and its possible regulators, suggesting that another signaling pathway was involved in the downregulation of CD147. This is the first study to show the downregulation of CD147 by Ad-REIC in prostate cancer cells. At least some of the therapeutic effects of Ad-REIC may be due to the downregulation of the cancer-progression factor, CD147.
|
キーワード | prostate cancer
REIC/Dkk-3
CD147
cell growth
p38 MAP kinase
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2017-04
|
巻 | 71巻
|
号 | 2号
|
出版者 | Okayama University Medical School
|
開始ページ | 135
|
終了ページ | 142
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2017 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID |